drugset / Trial / NCT00016302

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00016302

Completed 100 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. This phase II trial is studying several different combination chemotherapy regimens to see how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia

Timeline

Start
2001-04
Primary completion
2007-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelarabine Small molecule Intravenous
Background Cyclophosphamide Other / unclassified Intravenous
Background Cytarabine Small molecule Intravenous
Background Daunorubicin Small molecule Intravenous
Background Dexamethasone Small molecule Oral
Background Doxorubicin Other / unclassified Intravenous
Background Leucovorin Small molecule Intravenous
Background MERCAPTOPURINE ANHYDROUS Small molecule Oral
Background Methotrexate Small molecule Intrathecal
Background Pegaspargase Protein / enzyme biologic Intramuscular
Background Prednisone Other / unclassified Oral
Background Thioguanine Small molecule Oral
Background Vincristine Small molecule Intravenous
Background asparaginase Protein / enzyme biologic Intramuscular